Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19 ; volume:10 ; number:1 ; day:18 ; month:11 ; year:2020 ; pages:1-10 ; date:12.2020
Scientific reports ; 10, Heft 1 (18.11.2020), 1-10, 12.2020
- Urheber
-
Kuo, Tsun-Yung
Lin, Meei-Yun
Coffman, Robert L.
Campbell, John D.
Traquina, Paula
Lin, Yi-Jiun
Liu, Luke Tzu-Chi
Cheng, Jinyi
Wu, Yu-Chi
Wu, Chung-Chin
Tang, Wei-Hsuan
Huang, Chung-Guei
Tsao, Kuo-Chien
Chen, Charles
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-020-77077-z
- URN
-
urn:nbn:de:101:1-2020122318592307449815
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kuo, Tsun-Yung
- Lin, Meei-Yun
- Coffman, Robert L.
- Campbell, John D.
- Traquina, Paula
- Lin, Yi-Jiun
- Liu, Luke Tzu-Chi
- Cheng, Jinyi
- Wu, Yu-Chi
- Wu, Chung-Chin
- Tang, Wei-Hsuan
- Huang, Chung-Guei
- Tsao, Kuo-Chien
- Chen, Charles
- SpringerLink (Online service)
Ähnliche Objekte (12)
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice
Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
Mucosal immunization with a delta-inulin adjuvanted recombinant spike vaccine elicits lung-resident immune memory and protects mice against SARS-CoV-2
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge
Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice
Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
Mucosal immunization with a delta-inulin adjuvanted recombinant spike vaccine elicits lung-resident immune memory and protects mice against SARS-CoV-2
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge
Comment on “Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine”
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects
A CpG 1018 adjuvanted neuraminidase vaccine provides robust protection from influenza virus challenge in mice
Down selecting adjuvanted vaccine formulations: a comparative method for harmonized evaluation
Post-Marketing Safety Surveillance for the Adjuvanted Recombinant Zoster Vaccine: Methodology
Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters
A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein
Mucosal immunization with a delta-inulin adjuvanted recombinant spike vaccine elicits lung-resident immune memory and protects mice against SARS-CoV-2
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge